> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# GLP-1 receptor agonist cancer benefits may reflect immortal time bias in study design
- URL: https://www.coios.me/glp-1-receptor-agonist-cancer-benefits-may-reflect-immortal/
- Published: 2026-11-22T13:08:12.000Z
- Updated: 2026-11-22T13:54:15.000Z
- Description: Simulated study designs with no true effect gave hazard ratios of 0.39 to 0.85, close to published GLP-1 cancer estimates.
- Author: Daniel Ryan
- Tags: Health today, Obesity, diabetes and GLP-1, #peer-reviewed, #contradicts, #item, #source-2026-11, #score-68

The authors examined two observational studies citing target trial emulation that linked GLP-1 receptor agonists with lower cancer risk. Both counted patients as exposed after a second prescription but started follow-up at the first. Monte Carlo simulation reproduced these designs, with 500 replications of 5,000 people and a true hazard ratio of 1.0\. Varying the gap between prescriptions gave hazard ratios of 0.72 to 0.39 over longer follow-up, 0.85 to 0.60 over shorter. Aligning eligibility, treatment assignment and time zero removed the bias and recovered hazard ratios centred on 1.0\. The work uses simulated data only and does not re-analyse the original patient records.

*Why it is interesting: Recent observational studies reported large protective associations between GLP-1 receptor agonists and cancer. This simulation shows similar estimates arise when exposure is defined after time zero, with no true effect.*

Source

[Journal of Clinical Epidemiology, 20 November 2026](https://doi.org/10.1016/j.jclinepi.2026.112595?ref=coios.me)

Paper

Laundered Survival: When Target Trial Emulation Doesn't Emulate-Implications for GLP-1 Receptor Agonists and Cancer Outcomes

Authors

Brophy JM

DOI

10.1016/j.jclinepi.2026.112595

Type

Peer-reviewed article

Design

Conceptual appraisal plus Monte Carlo simulation (500 replications, n=5,000 each) reproducing two published GLP-1/cancer target trial emulation designs under a null hazard ratio

Verdict

Contradicts prior evidence

Driver

[Obesity, diabetes and GLP-1](https://www.coios.me/d-obesity-diabetes/)